ERBB2 and breast carcinoma: Trastuzumab (HerceptinTM, Genentech, South San Francisco, CA, USA) is a monoclonal antibody that targets the extracellular domain of HER2 and is widely used for the treatment of HER2 positive breast cancer [7].